WO2002053165A1 - Composition naturelle anti-angiogenique, son procede de preparation et son application - Google Patents

Composition naturelle anti-angiogenique, son procede de preparation et son application Download PDF

Info

Publication number
WO2002053165A1
WO2002053165A1 PCT/CN2000/000740 CN0000740W WO02053165A1 WO 2002053165 A1 WO2002053165 A1 WO 2002053165A1 CN 0000740 W CN0000740 W CN 0000740W WO 02053165 A1 WO02053165 A1 WO 02053165A1
Authority
WO
WIPO (PCT)
Prior art keywords
solvent
trichosanthin
extract
composition
preparation
Prior art date
Application number
PCT/CN2000/000740
Other languages
English (en)
Chinese (zh)
Inventor
Yang Ke
Guirong Lu
Yueqi Wang
He Pang
Tao Ning
Original Assignee
Beijing Insititute For Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Insititute For Cancer Research filed Critical Beijing Insititute For Cancer Research
Priority to PCT/CN2000/000740 priority Critical patent/WO2002053165A1/fr
Priority to CNB008200327A priority patent/CN1230186C/zh
Publication of WO2002053165A1 publication Critical patent/WO2002053165A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A61K36/428—Trichosanthes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention belongs to the field of tumor biomedicine, and particularly relates to a natural anti-angiogenesis chemical component extracted from trichosanthin, and also relates to a preparation method of the chemical component and uses as an angiogenesis inhibitor and an anti-tumor drug. Background of the invention
  • the natural anti-angiogenic composition is obtained from a solvent-extracted extract of a trichosanthin drug substance at normal temperature and pressure, and is a product obtained after the extract is subjected to solvent treatment and column chromatography at least once.
  • the solvent includes methanol, ethanol, and acetone.
  • a method for extracting the natural anti-angiogenic composition is provided: Chinese medicine trichosanthin is used as a raw material, which is pretreated into a powder with a particle size of about 20 mesh or less, and is used at normal temperature and pressure. Solvent extraction. The extract was concentrated and separated by multiple solvent treatments and column chromatography.
  • additives and the above-mentioned anti-angiogenic components can be prepared into corresponding preparations according to the conventional methods and pharmacodynamic requirements in the pharmaceutical field, such as Oral preparations such as capsules, tablets, oral liquids, granules, and syrups, and non-oral preparations such as injections and powder injections, among which intravenous injections are preferred.
  • Oral preparations such as capsules, tablets, oral liquids, granules, and syrups
  • non-oral preparations such as injections and powder injections, among which intravenous injections are preferred.
  • composition ingredients hereinafter referred to as short
  • T3 Take the extract product T3 obtained in Example 1 and formulate the test drug with a concentration of 0.5 g / ml with deionized water.
  • S-180 sarcomas passaged from ascites were diluted with saline 1: 5, approximately 1 X 107 cells / ml, and inoculated to female Kunming germline mice (body weight approximately 20g) 0.2ml subcutaneously in the right armpit. After the inoculation, they were randomly divided into groups of no less than 10 mice.
  • T3 drug at a concentration of 3 g / ml was administered orally to 0.3 ml / day / only.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention se rapporte à un type de composition naturelle anti-angiogénique, à son procédé de préparation et à son application sous forme d'inhibiteur angiogénique et de médicament anti-cancéreux. La composition peut-être obtenue par extraction de Radix Trichosanthes dans un solvant à une température et une pression normales, qui est ensuite soumis à un traitement avec un type de solvant et à une chromatographie sur colonne afin de séparer les hydrates de carbone obtenus au moins une fois. Grâce au test biologique anti-angiogénèse in vivo, au test biologique de culture cellulaire in vitro et au test de biologique anti-cancéreux menés sur les animaux, le principe actif extrait du Radix Trichosanthes fait preuve d'une activité anti-angiogénique et anti-cancéreuse.
PCT/CN2000/000740 2000-12-29 2000-12-29 Composition naturelle anti-angiogenique, son procede de preparation et son application WO2002053165A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/CN2000/000740 WO2002053165A1 (fr) 2000-12-29 2000-12-29 Composition naturelle anti-angiogenique, son procede de preparation et son application
CNB008200327A CN1230186C (zh) 2000-12-29 2000-12-29 天然血管生成抑制组分及其制备方法和用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2000/000740 WO2002053165A1 (fr) 2000-12-29 2000-12-29 Composition naturelle anti-angiogenique, son procede de preparation et son application

Publications (1)

Publication Number Publication Date
WO2002053165A1 true WO2002053165A1 (fr) 2002-07-11

Family

ID=4574763

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2000/000740 WO2002053165A1 (fr) 2000-12-29 2000-12-29 Composition naturelle anti-angiogenique, son procede de preparation et son application

Country Status (2)

Country Link
CN (1) CN1230186C (fr)
WO (1) WO2002053165A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1046680A (zh) * 1989-04-29 1990-11-07 中国科学院上海有机化学研究所 兽用天花粉蛋白胶囊的生产方法
KR940001730B1 (ko) * 1991-07-15 1994-03-05 주식회사 선경인더스트리 괄루근으로부터 생체활성다당의 제조방법
CN1173995A (zh) * 1997-07-30 1998-02-25 杨圣水 一种免疫饮料
US5910307A (en) * 1996-09-19 1999-06-08 Sunkyong Industries, Ltd. Process of extracting and purifying biologically effective ingredients from combined medicinal plants and their extract composition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1046680A (zh) * 1989-04-29 1990-11-07 中国科学院上海有机化学研究所 兽用天花粉蛋白胶囊的生产方法
KR940001730B1 (ko) * 1991-07-15 1994-03-05 주식회사 선경인더스트리 괄루근으로부터 생체활성다당의 제조방법
US5910307A (en) * 1996-09-19 1999-06-08 Sunkyong Industries, Ltd. Process of extracting and purifying biologically effective ingredients from combined medicinal plants and their extract composition
CN1173995A (zh) * 1997-07-30 1998-02-25 杨圣水 一种免疫饮料

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GUO FENG ET AL.: "The effect of radix trichosanthis on immunologic function of human erythrocyte", JOURNAL OF THE PLA'S MEDICINE, vol. 23, no. 5, 1998, pages 455 - 457 *

Also Published As

Publication number Publication date
CN1230186C (zh) 2005-12-07
CN1482915A (zh) 2004-03-17

Similar Documents

Publication Publication Date Title
WO2015090180A1 (fr) Arab-galactane de fleur sanchi, procédé de préparation et utilisation
JP6656316B2 (ja) ハマナツメの使用方法、ハマナツメ抽出物の使用方法及び薬物混合物の使用方法
CN110548037A (zh) 精制熊胆粉及其增强体质治疗和预防肿瘤和癌症的用途
CN112168833A (zh) 知母皂苷酶解产物及其主要组分知母皂苷aⅲ的医药用途
US20050287230A1 (en) Method of producing ginsenoside 20 (R)-Rh2 and composition of matter thereof
CN110917181B (zh) 一种甘草查尔酮b的分离方法及应用
CN108329381A (zh) 一种来源于麒麟菜的十六肽及其在制备防治恶性肿瘤转移药物中的应用
CN101723997A (zh) 葛根素糖基化衍生物、其药物组合物、及其制备方法和用途
JP2000503686A (ja) 黄栢皮とオミナエシ植物の混合抽出物を含有するｃ型肝炎治療用製薬組成物
CN115998754A (zh) 皂苷衍生物在制备用于治疗和预防溃疡性结肠炎药物中的用途、制备方法及应用
KR102659740B1 (ko) 해삼 생식선 추출물 또는 이로부터 유래된 화합물의 항암 용도
WO2002053165A1 (fr) Composition naturelle anti-angiogenique, son procede de preparation et son application
AU2020103978A4 (en) Sea cucumber intestinal peptide and preparation method and use thereof
CN112979640B (zh) 一类生物碱二聚体类化合物及其在制备pd-1/pd-l1通路抑制剂中的应用
CN112891361B (zh) Pubescenoside C在制备防治心肌缺血再灌注损伤药物中的应用
CN110063960A (zh) 3-氢化松苓酸b氰甲酯的制药用途
CN105524135B (zh) 毛酸浆内酯的制备方法及其在制备抗肿瘤药物中的应用
CN105732736B (zh) 一种苯丙素类化合物的制备方法
CN105708845B (zh) 一种苯丙素类化合物及其药学上可接受的盐在制备治疗炎症性疾病的药物中的应用
CN111297849B (zh) 用于治疗喉癌的药物组合物、其制备方法及其应用
CN114601828B (zh) 一种雪灵芝提取物及其在制备抗炎药物中的用途
CN115192587B (zh) 一种枸杞子寡糖的新用途
CN114478700B (zh) 鸡冠花子中荨麻科类型环肽的制备方法及其在抗肿瘤药物中的应用
US10329316B2 (en) Phenylpropanoid compound and preparation method and use thereof
CN1513862A (zh) 车前草总苷的制备工艺及其在医药中的应用

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 008200327

Country of ref document: CN

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP